MX2023010445A - Antagonistas de actrii-alk4 y metodos para tratar la insuficiencia cardiaca. - Google Patents
Antagonistas de actrii-alk4 y metodos para tratar la insuficiencia cardiaca.Info
- Publication number
- MX2023010445A MX2023010445A MX2023010445A MX2023010445A MX2023010445A MX 2023010445 A MX2023010445 A MX 2023010445A MX 2023010445 A MX2023010445 A MX 2023010445A MX 2023010445 A MX2023010445 A MX 2023010445A MX 2023010445 A MX2023010445 A MX 2023010445A
- Authority
- MX
- Mexico
- Prior art keywords
- actrii
- alk4
- heart failure
- antagonists
- methods
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 6
- 239000005557 antagonist Substances 0.000 title abstract 4
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163159051P | 2021-03-10 | 2021-03-10 | |
| US202163227149P | 2021-07-29 | 2021-07-29 | |
| PCT/US2022/019570 WO2022192411A1 (en) | 2021-03-10 | 2022-03-09 | Actrii-alk4 antagonists and methods of treating heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010445A true MX2023010445A (es) | 2023-11-22 |
Family
ID=83228302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010445A MX2023010445A (es) | 2021-03-10 | 2022-03-09 | Antagonistas de actrii-alk4 y metodos para tratar la insuficiencia cardiaca. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250064952A1 (https=) |
| EP (1) | EP4305052A4 (https=) |
| JP (1) | JP2024511316A (https=) |
| KR (1) | KR20230169124A (https=) |
| AU (2) | AU2022235083A1 (https=) |
| BR (1) | BR112023018283A2 (https=) |
| CA (1) | CA3211507A1 (https=) |
| MX (1) | MX2023010445A (https=) |
| WO (1) | WO2022192411A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024336884A1 (en) * | 2023-09-08 | 2026-03-26 | 35Pharma Inc. | Combination therapy with actriib receptor variants and glp-1 agonists |
| WO2025250605A1 (en) * | 2024-05-31 | 2025-12-04 | Eli Lilly And Company | Acvr2a and acvr2b rna interference agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41920B1 (fr) * | 2015-04-06 | 2021-05-31 | Acceleron Pharma Inc | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
| MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| DK3496739T3 (da) * | 2016-07-15 | 2021-05-10 | Acceleron Pharma Inc | Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension |
| CA3039573A1 (en) * | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Alk4:actriib heteromultimers and uses thereof |
| GB201620119D0 (en) * | 2016-11-29 | 2017-01-11 | Pharmafox Therapeutics Ag | Compounds |
| JP7669291B2 (ja) * | 2019-05-30 | 2025-04-28 | アクセレロン ファーマ インコーポレーテッド | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
| JP2023534127A (ja) * | 2020-06-17 | 2023-08-08 | アクセルロン ファーマ インコーポレイテッド | ＡｃｔＲＩＩ－ＡＬＫ４アンタゴニストおよび心不全を処置する方法 |
-
2022
- 2022-03-09 WO PCT/US2022/019570 patent/WO2022192411A1/en not_active Ceased
- 2022-03-09 KR KR1020237034040A patent/KR20230169124A/ko active Pending
- 2022-03-09 CA CA3211507A patent/CA3211507A1/en active Pending
- 2022-03-09 AU AU2022235083A patent/AU2022235083A1/en not_active Abandoned
- 2022-03-09 MX MX2023010445A patent/MX2023010445A/es unknown
- 2022-03-09 US US18/549,474 patent/US20250064952A1/en active Pending
- 2022-03-09 EP EP22767907.3A patent/EP4305052A4/en active Pending
- 2022-03-09 JP JP2023554809A patent/JP2024511316A/ja active Pending
- 2022-03-09 BR BR112023018283A patent/BR112023018283A2/pt unknown
-
2025
- 2025-09-11 AU AU2025230744A patent/AU2025230744A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4305052A4 (en) | 2025-01-01 |
| AU2022235083A1 (en) | 2023-09-21 |
| JP2024511316A (ja) | 2024-03-13 |
| CA3211507A1 (en) | 2022-09-15 |
| US20250064952A1 (en) | 2025-02-27 |
| EP4305052A1 (en) | 2024-01-17 |
| WO2022192411A1 (en) | 2022-09-15 |
| KR20230169124A (ko) | 2023-12-15 |
| BR112023018283A2 (pt) | 2023-10-31 |
| AU2025230744A1 (en) | 2025-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022016243A (es) | Antagonistas de actrii-alk4 y métodos para el tratamiento contra insuficiencia cardíaca. | |
| CY1124277T1 (el) | Συνθεσεις που περιλαμβανουν πολυπεπτιδα actriia για χρηση στη θεραπεια πνευμονικης υπερτασης | |
| MX2023010445A (es) | Antagonistas de actrii-alk4 y metodos para tratar la insuficiencia cardiaca. | |
| MX2024003145A (es) | Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol. | |
| MX386595B (es) | Métodos para el tratamiento del sobrepeso o la obesidad. | |
| CY1124616T1 (el) | Θεραπεια της μετα-βαριατρικης υπογλυκαιμιας με εξενδινη(9-39) | |
| MX2021013631A (es) | Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis. | |
| MX2023014840A (es) | Un inhibidor de la vía de la miostatina en combinación con un activador de la vía de la glp-1 para su uso en el tratamiento de trastornos metabólicos. | |
| EA201891946A1 (ru) | Коагонисты глюкагона и glp-1 для лечения ожирения | |
| MX390722B (es) | Tratamiento de resistencia a diureticos. | |
| MX2022000812A (es) | Metodos de tratamiento de hiperplasia suprarrenal congenita. | |
| MX387305B (es) | Tratamiento de adipocitos | |
| MX2018014621A (es) | Composicion biopesticida para uso en la prevencion o para minimizar la enfermedad de la planta. | |
| BR112022007721A2 (pt) | Método para o tratamento da demência | |
| PH12015502100A1 (en) | Reducing the risk of autoimmune disease | |
| BR112017013845A2 (pt) | derivados de glucagon | |
| WO2018081401A8 (en) | METHOD FOR INCREASING CELL PROLIFERATION IN BETA PANCREATIC CELLS, PROCESSING METHOD AND COMPOSITION | |
| EP3695841A3 (en) | Ship inhibition to combat obesity | |
| BR112022003054A2 (pt) | Composições e métodos que usam adenosilcobalamina | |
| MY202857A (en) | Method of treating hyperglycemia | |
| MX2021006540A (es) | Compuestos farmaceuticos y su uso como inhibidores de proteasa 19 especifica de ubiquitina (usp19). | |
| EA202192296A1 (ru) | Терапевтическое применение дулаглутида | |
| MX2021015034A (es) | Composiciones de lactobacillus y usos de las mismas. | |
| EP4246324A3 (en) | Apparatus and method for reducing an energy consumption of hardware based on an application state | |
| BR112023018256A2 (pt) | Antagonistas de actrii-alk4 e métodos para tratar insuficiência cardíaca |